Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/06/025818
CTRI/2020/06/025818Not yet recruiting未知

Efficacy and safety of combination of cholecalciferol and Curcuma longa as an add-on therapy to standard R-CHOP in Diffuse Large Bcell Lymphoma (DLBCL) - a randomized open label 2x2 factorial trial - E-SCHOLAR

JIPMER Intramural fund0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Newly diagnosed patients of diffuse large B cell lymphoma (DLBCL) [based on the 2008 World Health Organization classification] to be started on R-CHOP with serum 25 hydroxy D level less than

Exclusion Criteria

  • •Subjects previously treated with chemotherapy except for prefix chemotherapy, radiotherapy, immunotherapy or experimental therapies for lymphoma or other malignancy.
  • •History of other cancer within the past 5 years except curatively treated non- melanoma skin cancer or in situ carcinoma of
  • •uterine cervix.
  • •Subjects diagnosed with double hit or triple
  • •hit lymphoma.

Investigators

Sponsor
JIPMER Intramural fund

Similar Trials

Not yet recruiting
Phase 3
Efficacy and Safety of Chelation Therapy with Calcium Disodium EDTA (ethylenediaminetetraacetic acid) in the Progression of Chronic Kidney Disease of Unknown Etiology in Sri LankaChronic Kidney Disease of Unknown Etiology
SLCTR/2018/021niversity of Colombo
Completed
Phase 2
Effect of Combined Use of Calcium and Vitamin B6 on premenstrual Syndromepremenstrual syndrome.premenstrual tension syndrome
IRCT2014070313405N3Vice Chancellor of Research of Hamedan University of Medical Sciences76
Active, not recruiting
Not Applicable
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidism
EUCTR2010-018861-53-NLeiden University Medical Center
Not yet recruiting
Phase 2
comparative evaluation of three different root canal medicaments in reducing pai
CTRI/2024/08/071970Dr Itika Jain
Completed
Not Applicable
Combined oral iron chelation in thalassemia
CTRI/2018/02/012134JIPMER23